Document 0828
 DOCN  M9480828
 TI    Antigen clearance for evaluation of treatment of histoplasmosis.
 DT    9410
 AU    Blair R; Garringer T; Limjoco M; Korzun A; Hafner R; Wheat J; Indiana
       University, Indianapolis.
 SO    Abstr Gen Meet Am Soc Microbiol. 1994;94:605 (abstract no. F-95). Unique
       Identifier : AIDSLINE ASM94/94313117
 AB    Evaluation of new antifungal agents may be assisted by measurement of
       Histoplasma antigen clearance. We compared antigen clearance in patients
       treated successfully with itraconazole to that in historical controls
       treated with amphotericin B. Patients receiving itra were participants
       in an AIDS Clinical Trials Group protocol. The historical control group
       included AIDS patients treated with ampho B from 1988 to 1992. Antigen
       clearance was measured by radioimmunoassay, testing samples at baseline
       and at the end of induction treatment in a single assay to allow direct
       comparison. Antigenuria cleared more rapidly in patients treated with
       ampho B than with itra. TABULAR DATA, SEE ABSTRACT VOLUME. Antigenemia
       clearance was similar in both groups. This rate of clearance of antigen
       correlates with clinical evidence of more rapid response to treatment
       with ampho B than itra, namely defervescence. Clearance of antigen may
       complement clinical and cultural markers for evaluation of antifungal
       therapy for histoplasmosis.
 DE    Acquired Immunodeficiency Syndrome/THERAPY  Amphotericin B/*THERAPEUTIC
       USE  Antigens, Fungal/*BLOOD/URINE  AIDS-Related Opportunistic
       Infections/*PREVENTION & CONTROL  Comparative Study
       Histoplasma/*IMMUNOLOGY  Histoplasmosis/*PREVENTION & CONTROL  Human
       Itraconazole/*THERAPEUTIC USE  Metabolic Clearance Rate  CLINICAL TRIAL
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).